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Abstract
Background: Reduced N-acetyl-aspartate (NAA) levels in magnetic resonance spectroscopy (MRS) may visualize axonal
damage even in the normal appearing white matter (NAWM). Demyelination and axonal degeneration are a hallmark in
multiple sclerosis (MS).
Objective: To define the extent of axonal degeneration in the NAWM in the remote from focal lesions in patients with
relapsing-remitting (RRMS) and secondary progressive MS (SPMS).
Material and Methods: 37 patients with clinical definite MS (27 with RRMS, 10 with SPMS) and 8 controls were included. We
used 2D
1H-MR-chemical shift imaging (TR=1500ms, TE=135ms, nominal resolution 1ccm) operating at 3Tesla to assess the
metabolic pattern in the fronto–parietal NAWM. Ratios of NAA to creatine (Cr) and choline (Cho) and absolute
concentrations of the metabolites in the NAWM were measured in each voxel matching exclusively white matter on the
anatomical T2 weighted MR images.
Results: No significant difference of absolute concentrations for NAA, Cr and Cho or metabolite ratios were found between
RRMS and controls. In SPMS, the NAA/Cr ratio and absolute concentrations for NAA and Cr were significantly reduced
compared to RRMS and to controls.
Conclusions: In our study SPMS patients, but not RRMS patients were characterized by low NAA levels. Reduced NAA-levels
in the NAWM of patients with MS is a feature of progression.
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Introduction
MS is a chronic inflammatory disease of the central nervous
system (CNS) of unknown origin causing demyelination and
axonal degeneration [1]. The immune reaction in MS patients is
heterogeneous and compartmentalized within the CNS. It may be
triggered temporarily or may take a continuous course [2–4].
The diagnosis of clinical definite MS is established by typical
clinical symptoms, a relapsing remitting course and paraclinical
findings in magnetic resonance imaging (MRI) and cerebrospinal
fluid (CSF) [5–7]. Other disorders which may mimic MS must be
ruled out.
In most cases MS follows a relapsing-remitting course (RRMS)
with clearly defined relapses and no progression during clinical
remissions [5]. It is unclear why MS sometimes follows a benign
RRMS course while in other cases converting into a progressive-
relapsing course, with or without superposed relapses (SPMS). It is
further unknown, why MRI lesion load does not consistently
correlate to clinical disability [5–8]. Supposedly even in very early
stages of RRMS a ‘‘clinical silent’’ focal or diffuse ‘‘background
inflammation’’ not detectable in conventional MRI may progress
and cause diffuse axonal damage. This subtle axonal degeneration
may be visualized by magnetic resonance spectroscopy (
1H-MRS)
as reduction of N-acetyl-aspartate (NAA) levels [9–14]. These
results are, however, controversially discussed, due to new insights
from the recently improved
1H-MRS technique. Higher field
strengths (3 Tesla) and chemical shift imaging have substantially
increased the validity of
1H-MRS. To our knowledge, so far only
one study using multivoxel
1H-MR 2D spectroscopic imaging
(MRSI) operating at 3 Tesla was published [15]. In this study,
Kirov et al. found no reduction of NAA levels in 21 mildly disabled
RRMS patients (mean expanded disability status scale (EDSS) of
1.4., mean disease duration of 2.3 years) compared to 15 matched
controls.
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11625The aim of our study was to define the axonal changes in the
normal appearing white matter (NAWM) of SPMS and secondly,
to reassess whether or not reduced NAA levels could be found in
the NAWM of RRMS with improved MRSI operating at 3 Tesla.
Materials and Methods
Subjects
The study was approved by the local Ethics Committee
(Commission of Medical Ethics of Vienna; Ethic Approval/
Registration Number: EK 06-169-VK). Informed written consent
was obtained from all patients and volunteers.
In total, 37 patients with clinically definite MS and character-
istic MRI and CSF findings were included [6]. All patients showed
oligoclonal bands. Twenty-seven patients followed a relapsing-
remitting course with well defined relapses and lack of clinical
progression between relapses. The RRMS patients were compared
to 10 SPMS patients and 8 healthy controls (mean age, 46.3
years66.3 [range, 17.0 to 65.0], female:male=7:1). A complete
survey of clinical data is given in table 1.
MRI and MRS
We used the same standardized protocol for
1H-MR 2D
Spectroscopic Imaging (MRSI) as described in detail previously [16].
MRSI at magnetic field strength of 3 Tesla (TimTrio equipped
with standard head 8 channel receive coil, Siemens Healthcare,
Erlangen, Germany) was applied to assess the metabolic pattern in
the NAWM. MRSI measurements were performed parallel to axial
T1- and T2-weighted slices. Routine automatic adjustments were
applied prior to data acquisition. PRESS sequence was used for
rectangular VOI selection (86861 cm) in the fronto-parietal white
matter well above lateral ventricles. Special care was taken to avoid
skull and subcutaneous tissue contamination. CHESS sequence was
used for water suppression. Sequence parameters included TR/TE
1500/135 ms, 16616 elliptical weighted phase encoding steps across
a1 6 616 cm FOV, slice thickness of 1cm, 50% Hanning filter and 3
averages. To obtain intern quantification reference additional scan
with the same timing and geometrical parameters was taken without
water suppression. The acquisition time of spectroscopic sequences
w a sl e s st h a n1 5m i n u t e s .
Quantification of the spectra was performed off-line in the time
domain using jMRUI software package [17]. Signals from voxels
(8–12 voxels per RRMS patients and healthy controls, 3–8 voxels
in SPMS patients) matching exclusively frontal and fronto-parietal
white matter without any signs of lesion load on conventional T2
weighted images were selected. For the processing of metabolite
spectra, remaining water signal was removed using HLSVD filter
and amplitudes of Cho, Cr and NAA signals were calculated with
AMARES [18–19]. Amplitude of water signal for each processed
voxel was assessed from the scan without water suppression.
Concentrations of metabolites are given as ratios of signal
intensities of NAA to Cr, NAA to Cho, and Cho to Cr
respectively. Additionally, absolute concentrations of Cho, Cr
and NAA were calculated using water signal from the identical
voxel as internal reference. Mono exponential spin-lattice and
spin-spin relaxation was assumed and published values of T1
(water: 832 ms; Cho: 1080 ms; Cr: 1240 ms; NAA: 1350 ms) and
T2 (water: 110 ms; Cho: 187 ms; Cr: 156 ms; NAA: 295 ms)
relaxation times of water and respective metabolites measured at
3T in NAWM of healthy volunteers were used for relaxation
corrections [20–23]. The concentrations were calculated accord-
ing to Kreis et al. as follows [24]:
Cm~ Sm=Sw ðÞ   Cw   nw=nm ðÞ   fw
T1=fm
T1 
  fw
T2=fm
T2 
where C stands for concentration, S for signal intensity, n for the
number of chemically equivalent protons, f
T1 for spin-lattice
relaxation function (1-e
TR/T1), fT2 for spin-spin relaxation
function (e
2TE/T2) and the indexes m for metabolite and w for
water. Cw was for white matter was chosen 35880 mmol/l
according to Ernst et al. [25].
Statistical analysis
Metabolic ratios and absolute concentrations obtained from
individual voxels in NAWM were averaged for every patient.
Intra-patient coefficient of variation averaged at 10% for Cho;
12% for Cr and 11% for NAA. Data are given as means for
patient group. For statistical analysis nonparametric tests (Mann-
Whitney, Kolmogorov-Smirnov) were applied (Statgraphics plus
). All tests were classified as significant if the p-value was ,0.05.
Results
We studied 27 RRMS (mean disease duration, 5.6 years), 10
SPMS (mean disease duration, 12.7 years), and 8 healthy controls.
Concentrations of metabolites were quantified in relation to each
Table 1. Included MS patients.
patients female:male
age at onset
± STD (years)
[range]
disease duration
± STD (months)
[range]
number of relapses
± STD
EDSS
at MRS
RRMS total, n=27 30.2±2.2
[13.0 to 56.0]
79.5±14.2
[9.0 to 312.0]
3.9±0.4
[2 to 9]
1.7±0.3
[0.0 to 5.0]
female, n=23 29.462.5
[13.0 to 56.0]
88.1615.8
[14.0 to 312.0]
4.260.2
[2 to 9]
1.860.3
[0.0 to 5.0]
male, n=4 34.662.4
[30.0 to 40.0]
30.0616.8
[9.0 to 80.0]
2.2560.25
[2 to 3]
1.160.7
[0.0 to 3.0]
SPMS total, n=10 27.25±9.2
[13.0 to 41.5]
152.5±35.1
[14.0 to 324.0]
5.5±0.9
[2 to 10]
3.9±0.5
[3.0 to 6.5]
female, n=7 26.363.7
[13.0 to 41.5]
144.0646.4
[14.0 to 324.0]
5.361.0
[2 to 9]
3.460.2
[3.0 to 4.5]
male, n=3 29.565.3
[23.0 to 40.5]
172.3655.5
[78.0 to 278.0]
6.062.1
[3 to 10]
5.361.2
[3.0 to 6.5]
doi:10.1371/journal.pone.0011625.t001
3T MR Spectroscopy in MS
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water of well defined regions of NAWM, and compared to recently
published data [15].
Examples of MR spectra of RRMS, SPMS and healthy controls
are given in figure 1. Relative standard deviation of spectral fitting
for all included spectra was #5%. All MRS data of the NAWM
are presented in detail in figure 2 (ratios of metabolites, relative
concentrations) and in figure 3 (absolute metabolic concentra-
tions). Our results may be summarized briefly as follows.
1. Metabolite ratios, NAA/Cr, NAA/Cho and Cho/Cr
We found significant differences of metabolite ratios of RRMS
(n=27) compared to SPMS (n=10) (NAA/Cr, p,0.0003; NAA/
Cho, p,0.001), and between SPMS and controls (n=8) (NAA/
Cr, p,0.001; NAA/Cho, p,0.008).
No significant differences could be detected in all other
comparisons (RRMS vs. controls, NAA/Cr, NAA/Cho and
Cho/Cr and SPMS vs. controls, Cho/Cr) (figure 2).
2. Absolute metabolite concentrations [mM], NAA, Cr and
Cho
NAA (figure 3, white symbols). No significant difference of
absolute NAA concentrations was found between RRMS (n=27;
NAA [mM] mean=12.460.5; range 10.1 to 14.7) and controls
(n=8; NAA [mM] mean=12.360.4; range 10.1 to 13.6). In
SPMS NAA-levels (n=10; NAA [mM] mean=8.660.7; range 4.9
to 11.1) were significantly reduced compared to RRMS (n=27;
p,0.00001) and to controls (n=8; p,0.001).
Cr (figure 3, grey symbols). Absolute concentrations of Cr
were found significantly reduced in SPMS (n=10; Cr [mM]
Figure 1. Spectral region including resonance lines of choline (Cho), creatine (Cr) and N-acetyl-aspartate (NAA). Left column,
anatomical T2w MR Images with the depiction of MRSI PRESS box volume of interest (grey, 868 cm) and voxels (white) in the NAWM chosen for the
spectroscopic data evaluation. Right column, representative MR spectra from a single voxel with original spectra (lower trace), AMARES estimate
(second trace), individual components (third trace) and fit residue (upper trace). Data from RRMS (upper part) and SSPMS (middle part) patients as
well as healthy controls (CON, lower part) are presented.
doi:10.1371/journal.pone.0011625.g001
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[mM] mean=8.860.2; range 7.2 to 10.2) (p,0.0008). No
significant differences were found between SPMS and controls
(n=8; Cr [mM] mean=8.460.4; range 7.0 to 10.2), and between
RRMS patients and controls.
Cho (figure 3, black symbols). Absolute concentrations of
Cho differed slightly between RRMS (n=27; Cho [mM]
mean=2.660.1; range 2.1 to 3.3) and SPMS (n=10; Cho
[mM] mean=2.260.1; range 1.5 to 2.8) (p,0.2). No differences
of Cho concentrations were found between RRMS and controls
(Cho [mM] mean=2.560.1; range 2.1 to 3.2), and SPMS and
controls.
Relation of absolute metabolite concentrations and
EDSS. We found only a weak, but significant correlation
between reduced NAA levels and higher EDSS (linear
regression: correlation coefficient 20.48, R
2=23.4, standard
error for the estimate=1.9, ANOVA table p,0.002). No
correlations were found between Cr or Cho concentrations and
EDSS.
In summary, we found a significant reduction of NAA/Cr and
NAA/Cho ratios and of absolute concentrations of NAA and Cr in
SPMS patients only. Between RRMS and controls, ratios and
absolute concentrations for the examined metabolites did not show
significant differences.
Discussion
In our study we analyzed NAA, Cr and Cho levels of the
NAWM of 37 MS patients and controls with multivoxel
1H-MRSI
operating at 3 Tesla. Our results for 27 RRMS patients and 8
controls are in accordance with recently published data of 21
RRMS and 15 controls [15]. In addition we found significant
changes in the NAWM of 10 SPMS.
1H-MRS allows an assessment of subtle metabolic changes
within the NAWM [12,14]. NAA is almost exclusively found in
active mitochondria of neurons and axons and is thus a marker of
axonal function and integrity [26]. Reduced levels of NAA are
suggestive for axonal degeneration or axonal loss, or both [26].
They may correlate to histopathological changes and proposed
histotoxic mechanisms in MS [4,27]. Whether reduced NAA levels
in MS patients reflect microscopic axonal changes due to primary
tissue damage, or due to axonal transection in remote demyelin-
ating lesions remains unclear [28]. While some studies found
decreased NAA levels in the NAWM of MS patients [28–29],
others did not [13,15,30]. These divergent results may be
explained by the very small and heterogeneous patient cohorts
(e.g. 2 RRMS and 12 SPMS aged from 28 to 61 years, and 4
controls aged 33 to 48 years in van Walderveen et al., 1999 [29]),
by the use of a 1.5 Tesla
1H-MRS and by the measurement of
metabolite ratios instead of absolute metabolite concentrations
[30–32].
The signal-to-noise ratio and spectral resolution are markedly
reduced in magnetic field strengths lower than 3 Tesla. This
suggests the use of
1H-MRS operating at 3 Tesla instead of 1.5
Tesla [11,32–33]. Furthermore only the improved MRSI allows
for a robust quantification of the respective signals simultaneously
in large brain regions [11,32–33].
Metabolite ratios are less sensitive than absolute concentrations
of individual metabolites [33,35]. The quantification of the
metabolite concentration is usually based on the metabolite signal
ratio to Cr which is regarded as ‘‘internal reference’’ for metabolite
ratios [34–35]. But the concentration of Cr may vary in different
pathological conditions and at different age [32,34–35]. The Cr
peak is composed of creatine and phosphocreatine. Cr occurs
mainly in glial cells, and is considered as a marker of cell energy
metabolism and mitochondrial function [34]. Increased Cr levels
may indicate glial cell proliferation or higher glial cell metabolism
and tissue repair mechanisms [32]. NAA levels might be normal,
because neuronal cell bodies remote from the focal or diffuse white
matter lesions may be unaffected and may maintain the axonal
transport of mitochondria to their distal ends. Markedly reduced
Cr levels might reflect the complete collapse of glial cell
metabolism preceding axonal changes, significant reduction of
glial cells, or tissue scar formation.
Lower NAA/Cr ratios must therefore not per se be interpreted
as axonal dysfunction or loss, if absolute NAA levels remain
unchanged but Cr levels are increased [31,34–37]. Vrenken et al.,
for example, found significantly reduced NAA/Cr ratios in the
NAWM of 76 MS patients (RRMS, SPMS and PPMS), while
absolute concentrations for NAA were not reduced but Cr was
increased [31]. They concluded that increased glial cell numbers,
and not axonal loss or dysfunction might be a common feature in
the NAWM of MS patients [31].
In conclusion, we want to emphasize that the normal NAA
levels found in our RRMS patients do not necessarily indicate
normal NAWM. Tissue changes in MS patients are heteroge-
neous and too complex to be detected by measuring only few
metabolites [4]. Spectral appearance and spin-spin relaxation
properties of further metabolites that might be changing in the
Figure 2. MRS Ratios of brain metabolite in NAWM of MS
patients and controls. white, NAA/Cr ratio; grey, NAA/Cho ratios;
black, Cho/Cr ratios; squares, RRMS patients (n=27); circles, SPMS
patients (n=10); triangles, controls (n=8); bars, means.
doi:10.1371/journal.pone.0011625.g002
Figure 3. MRS absolute concentrations of brain metabolite in
NAWM of MS patients and controls. white, NAA [mM]; grey,C r
[mM]; black, Cho [mM]. squares, RRMS patients (n=27); circles, SPMS
patients (n=10); triangles, controls (n=8); bars, means.
doi:10.1371/journal.pone.0011625.g003
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favour the measurements with shorter echo time, whereas flatter
spectral baseline at longer echo times increases the precision of
the NAA, Cr and Cho measurements.
MRSI was useful for demonstrating changes in the NAWM of
SPMS in our and in other studies clearly [13,29]. But there is still
an ongoing discussion, whether MRSI is sensitive to detect also
subtle axonal changes in the NAWM of benign or stable RRMS
patients. However, reduced NAA levels in RRMS without signs of
progression might be a strong indicator for clinically still
undetectable progressive axonal degeneration. This could identify
patients with progressive RRMS at a very early stage prior to
clinical deterioration [3–4]. MRS therefore may provide crucial
information for treatment decision, as lesion load does not
necessarily correlate with disease activity and progression
[1,3,8,38].
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